Overview

Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Vanderbilt University
Treatments:
Ketorolac
Ketorolac Tromethamine
Criteria
Inclusion Criteria:

- Adult volunteers

- Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite
maximal medical treatment

- Unable to tolerate corticosteroids due to side effects

Exclusion Criteria:

- 18 years or younger

- Have active ocular infection

- Pregnancy